Dianomi Therapeutics is expanding the use of its patented drug delivery system to include gene therapies.

This comes after licensing a second set of intellectual property from WARF.

The Madison-based startup is developing a technology known as mineral-coated microparticles, which can “stabilize and control” the release of therapeutic drugs and improve their effect. A release shows the MCM technology shares a capacity for biological molecule storage with human bones and teeth.

The MCM technology was developed by UW-Madison’s William Murphy, a professor of biomedical engineering and co-founder of Dianomi. He created the technology in hopes of improving upon artificial polymer-based drug delivery systems, which have more limited function.

“Dianomi has demonstrated success in developing and optimizing MCM delivery for biologics and other small molecules,” Murphy said in a release. “I look forward to Dianomi’s expansion into the area of nucleic acid therapy, building upon the early results of our nucleic acid delivery in regenerative medicine applications.”

Read the full story here.